Originating from the University of Geneva's laboratories through the distinguished efforts of Professors Olivier Jordan and Eric Allémann, our patented technology serves as the cornerstone for KYLYS AESTHETICS. 

 

We are pioneering a revolutionary approach with our biocompatible hyaluronan-based dermal filler, aiming to redefine the standards of comfort, safety, and efficacy with our patented technology. Our short-term goal is to complete the rigorous testing and documentation processes required for EU market approval, emphasizing biocompatibility testing, comprehensive clinical evaluation, and robust risk management.

 

Looking ahead, we aim for significant market expansion, notably entering the US market. Our path to market launch is defined by careful planning and adherence to the highest safety and efficacy standards, with our product undergoing thorough testing to meet ISO and regulatory standards for a Medical Device Class III designation.

​